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Abstract 
Background 
Fibroblast growth factor (FGF) 23 is a hormone that increases urinary phosphate excretion and 
regulates renal sodium reabsorption and plasma volume. We studied the role of plasma FGF23 in 
therapy optimization and outcomes in patients with new-onset and worsening heart failure (HF).  
Methods 
We measured plasma C-terminal FGF23 levels at baseline in 2399 of the 2516 patients included in 
the BIOlogy Study to Tailored Treatment in Chronic HF (BIOSTAT-CHF) trial. The association between 
FGF23 and outcome was evaluated by Cox regression analysis adjusted for potential confounders.  
Results 
Median FGF23 was 218.0 [IQR: 117.1-579.3] RU/ml; patients with higher FGF23 levels had a worse 
NYHA class, more signs of congestion, and were less likely to use an ACE-inhibitor (ACEi) or 
angiotensin receptor blocker (ARBs) at baseline (all P<0.01). Higher FGF23 levels were independently 
associated with higher BNP, lower eGFR, the presence of oedema and atrial fibrillation (all P<0.001). 
In addition, higher FGF23 was independently associated with impaired uptitration of ACEi/ARBs after 
3 months, but not of beta-blockers. In multivariable Cox regression analysis, FGF23 was 
independently associated with all-cause mortality (hazard ratio: 1.17 (1.09-1.26) per log increase, 
P<0.001), and the combined endpoint of all-cause mortality and HF hospitalization (1.15 (1.08-1.22) 
per log increase, P<0.001).   
Conclusions 
In patients with new-onset and worsening HF, higher plasma FGF23 levels were independently 
associated with volume overload, less successful uptitration of ACEi/ARBs and an increased risk of 
all-cause mortality and HF hospitalization. 
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Abbreviations 
ACEi  Angiotensin Converting Enzyme inhibitor 
ARB  Angiotensin Receptor Blocker 
BNP  Brain Natriuretic Peptide 
BIOSTAT-CHF BIOlogy Study to Tailored Treatment in Chronic Heart Failure 
CKD  Chronic Kidney Disease 
eGFR  estimated Glomerular Filtration Rate 
FGF23  Fibroblast Growth Factor 23 
HF  Heart Failure 
JVP  Jugular Venous Pressure 
NT-pro BNP N terminal pro Brain Natriuretic Peptide 
RAAS  Renin Angiotensin Aldosterone System 
 
Introduction 
The phosphaturic hormone fibroblast growth factor 23 (FGF23) is a key regulator of phosphate 
metabolism by inhibiting proximal tubular phosphate reabsorption in the kidney and suppressing the 
generation of 1,25(OH)2 vitamin D.[1] In patients with chronic kidney disease (CKD), higher FGF23 
levels have been consistently associated with an increased risk of cardiovascular morbidity and 
mortality.[2,3] FGF23 seems particularly strongly linked with heart failure [4], supported by 
mechanistic studies indicating that FGF23 contributes to the development of left ventricular 
hypertrophy (25), regulates renal sodium reabsorption and plasma volume and interacts with renin-
angiotensin-aldosterone system (RAAS) activation.[5-7] Furthermore, high FGF23 levels were 
associated with an impaired response to sodium restriction and ACE-inhibition in CKD patients.[8]  
Recently, elevated levels of FGF23 have been associated with cardiovascular mortality and incident 
heart failure in patients with stable ischemic heart disease.[9] In chronic heart failure, it has been 
suggested that FGF23 is associated with disease severity and adverse outcome.[10-13] Data on 
FGF23 in worsening or acute heart failure are scarce, even though it has been suggested that FGF23 
has a direct effect on sodium homeostasis and volume handling. The present study is the first to 
address the relation between FGF23, congestion, and clinical outcomes in new onset or worsening 
heart failure. FGF23 contributes to RAAS activation and angiotensin converting enzyme inhibitor 
(ACEi) therapy has been shown to be less effective in CKD patients with high FGF23 levels.(6,7) As 
such, or  as a consequence of the suspected association with congestion and more severe heart 
failure, FGF23 might have an effect on the ability to receive ACEi/angiotensin receptor blocker (ARB) 
therapy, a first line therapy in patients with heart failure. Therefore we additionally studied whether 
FGF23 is associated with impaired uptitration of ACEi/ARB. Based on the above, we hypothesized 
that a higher plasma FGF23 level in patients with acute or worsening heart failure is associated with 
less successful uptitration of guideline-recommended ACEi/ARB therapy and adverse clinical 
outcomes.  
 Methods 
Patient population 
The study design of the systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure 
(BIOSTAT-CHF) has been published previously.[14,15] In brief, the BIOSTAT-CHF trial is a large 
European, multicenter, multinational, prospective, observational study in which 2516 patients with 
new onset or worsening heart failure with either an ejection fraction of ≤40% or plasma 
concentrations of Brain Natriuretic Peptide (BNP) >400 pg/ml and/or N terminal pro Brain 
Natriuretic Peptide (NT-proBNP) >2,000 pg/ml, and treated with furosemide ≥40mg/day or 
equivalent, who were on ≤50% of the target dose of ACEi or ARB and beta-blocker therapy were 
enrolled. The trial was approved by the local ethics committee at each participating centre and 
complies with the declaration of Helsinki. All patients provided written informed consent.   
 
Study design 
Both inpatients and outpatients were enrolled, and had a visit at baseline and after 9 months of 
follow-up. During the first 3 months, the treating physician was encouraged to uptitrate ACEi/ARBs 
and beta-blockers to the target doses presented in the ESC heart failure guidelines.[16,17] 
Subsequently, patients were contacted every 6 months by telephone. At 9 months, reasons for not 
reaching the target dose were recorded. These unfortunately were most commonly described as 
“other” reason making this too unspecific for further analyses. Median follow-up was 21 months. 
The endpoints selected for these analyses were all-cause mortality, and the combined endpoint of 
all-cause mortality or first occurrence of HF hospitalization. HF hospitalization was defined as 
hospitalization lasting longer than one day for which the primary reason was worsening of signs or 
symptoms of HF, requiring intravenous medications or an increased dose of oral diuretics.  
 
Laboratory measurements 
From 2516 enrolled patients, plasma FGF23 was determined in 2399 (95.3%) available baseline 
plasma samples using a human C-terminal FGF23 ELISA (Immutopics, Inc., San Clemente, CA, USA). 
For the missing 117 patients (4.7%) no baseline plasma samples were available. More details on this 
specific assay, such as inter-/intra-assay variation have been described previously.[18] Using this 
assay, in a cohort of 3,107 community-living persons≥65 years of age median FGF23 was 70 [51-100] 
RU/mL.[19] Phosphate, calcium and albumin were measured in stored samples using routine 
laboratory procedures. Renin and aldosterone were both measured using a RadioImmunoAssay 
(Renin: CisBio International; Aldosterone: IBL International) in plasma samples that had previously 
undergone one freeze/thaw cycle. NT-proBNP was measured using Proseek Multiplex (Olink 
Biosciences AB, Uppsala, Sweden). Estimated glomerular filtration rate (eGFR) was calculated using 
the CKD-EPI eGFR formula.[20]  
 
Statistical analysis 
Data with a normal distribution are presented as mean ± standard deviation, and as frequencies and 
percentages for categorical values. Data with a skewed distribution are presented as median with 
interquartile ranges. Differences between quintiles of FGF23 were tested for significance with 
ANOVA (normal distribution), Kruskal-Wallis (skewed distribution), and Fisher’s exact test 
(categorical variables). A linear trend was statistically tested over quintiles of FGF23, after checking 
for non-linear trends. Uni- and multivariable linear regression analysis was performed with log 
transformed (using natural logarithm) FGF23 as a dependent variable. Transformations were 
checked using multifractional polynomials. Multivariable linear regression analysis, including all 
variables with p<0.10 in univariable analysis were constructed via backward elimination and 
validated using bootstrap re-sampling with 1,000 replicates. The model was tested for collinearity 
and checked by plotting residuals. Cox proportional hazard regression analysis was performed to 
examine associations with clinical outcomes. FGF23 was investigated as a continuous variable, and 
by quintiles. Multivariable models were adjusted for an outcome model specifically developed and 
validated in the BIOSTAT index and validation cohort with addition of markers that have previously 
been associated with FGF23 levels (renin, aldosterone, phosphate, albumin, calcium and eGFR, if not 
already included in the model).[21] The following variables were included in the BIOSTAT risk model 
for all-cause mortality: age, urea, NT-proBNP, haemoglobin, and use of beta-blocker at baseline.[21] 
The BIOSTAT risk model for HF hospitalization includes age, previous HF hospitalization, peripheral 
oedema, systolic blood pressure, and eGFR.[21] Finally, the risk model for the combined endpoint 
includes age, previous HF hospitalization, peripheral oedema, systolic blood pressure, NT-proBNP, 
haemoglobin, HDL, sodium, and use of beta-blocker at baseline.[21] Interaction analyses were used 
to test significant interactions in subgroups that may affect the association between FGF23 and 
outcome. These were visualized using forest plots. Logistic regression was used to investigate the 
association between FGF23 and ACEi/ARB use, and whether target dose was reached. For outcome 
analyses using data on ACEi/ARB use at 3 months, the outcome analyses were censored at 3 months. 
A two-tailed p-value <0.05 was considered statistically significant. All analyses were performed using 
R: a Language and Environment for Statistical Computing, version 3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria). 
 
Results 
Of the 2,399 patients enrolled, 1605 (67%) were hospitalized at the time of enrolment. Baseline 
characteristics per quintile of FGF23 are presented in table 1. Median FGF23 was 218.0 [117.1-579.3] 
RU/ml. Patients with a higher FGF23 level (i.e. being in a higher quintile of FGF23) were older, more 
often female, had a higher NYHA class, lower blood pressure, higher heart rate, and more signs of 
congestion (all P<0.005). The prevalence of all signs and symptoms of congestion, i.e. oedema, 
orthopnoea, jugular venous pressure (JVP), and hepatomegaly were greater in patients with higher 
FGF23 levels. In addition, patients with higher FGF23 levels were more likely to be hospitalized with 
worsening heart failure, had worse renal function, higher (NT-pro)BNP, and renin levels (all P<0.001). 
Also, these patients less frequently used ACEi or ARBs and beta-blockers, and a significantly lower 
percentage used target doses of both drugs.  
Correlates of log transformed FGF23 in multivariable linear regression are presented in 
supplementary table 1. The multivariable model had an overall r2 of 0.459, and the variables 
showing the strongest association with higher log FGF23 levels were higher NT-proBNP, the 
presence of atrial fibrillation and the presence of oedema. Also, higher aldosterone levels were 
independently associated with higher log FGF23 levels.  
 
FGF23 and therapy optimization 
Higher levels of FGF23 were associated with lower rates of ACEi/ARB and beta-blocker use at 
baseline (table 1). Also, patients with a higher FGF23 level less frequently used guideline-
recommended doses of ACEi/ARBs and beta-blockers (table 1). Furthermore, higher FGF23 levels 
were also inversely associated with ACEi/ARB use and dosage after 3 months of uptitration (table 2). 
This association remained significant after adjustment for baseline ACEi/ARB use, age, sex, eGFR, 
aldosterone, renin, calcium, albumin, phosphate, and NYHA class. In contrast, there was no 
significant independent association between FGF23 levels and beta-blocker use and dosage after 3 
months of uptitration (supplementary table 2). 
 
FGF23 and outcomes 
During a median follow-up of 21 [16-27] months, 631 out of the 2399 patients (26%) died, and 588 
patients (25%) were (re)hospitalized for HF. A total of 981 patients (41%) experienced the combined 
endpoint of all-cause mortality and/or HF hospitalization. In univariable Cox regression analysis, an 
increase in FGF23 was significantly associated with an increased risk of the combined endpoint, and 
remained independently associated after multivariable adjustment (HR: 1.15 [1.08-1.22] per log 
increase, P<0.001). Similar findings were observed in a multivariable Cox regression analysis where 
patients in the highest three quintiles of FGF23 had a significantly increased risk of the combined 
endpoint, compared to the lowest (first) quintile (table 3). The Kaplan Meier curve for the combined 
endpoint per quintile of FGF23 is presented in figure 1, and supplementary figure 1 shows the 
hazard ratio for FGF23 for the combined endpoint using a penalized spline function. Hazard ratios 
were consistent across subgroups based on ejection fraction, renal function, and RAAS activation 
(supplementary figure 2). There was also no significant difference in prognostic value in patients 
with new-onset or worsening heart failure or ischemic aetiology. There was a significant interaction 
with age, NYHA class, and new-onset or worsening heart failure, yet consistently across these 
subgroups higher FGF23 levels were also associated with a higher risk of the combined endpoint.  
Higher log FGF23 levels were also independently associated with all-cause mortality in univariable 
and multivariable analyses (HR: 1.17 [1.09-1.26] per log increase, P<0.001) and with cardiovascular 
mortality in uni- and multivariable analyses (supplementary table 3). The Kaplan Meier per quintile 
of FGF23 for all-cause mortality is shown in supplementary figure 3. The association of higher FGF23 
with outcome for both all-cause mortality and the combined endpoint persisted after additional 
adjustment for percentage of target dose reached after 3 months of uptitration (p<0.001 for both 
endpoints). The predictive value of FGF23 for all-cause mortality was comparable to that for NT-
proBNP, yet significantly higher (univariable Harrell’s c-statistic: 0.689 vs. 0.679, respectively, 
P<.001). Based on ROC analysis, the optimal cut-off of FGF23 for the prediction of all-cause mortality 
is 315.2 RU/mL (AUC: 0.705). When FGF23 is added to a prognostic model that includes NT-proBNP, 
LVEF, ischemic etiology, age and sex, there was a significant gain in c-index, yet no significant change 
in NRI (supplementary table 4).  
 
Discussion 
In patients with new-onset and worsening HF, higher FGF23 levels were strongly and independently 
associated with an increased risk of all-cause mortality and heart failure hospitalization. Patients 
with a higher FGF23 level had more severe heart failure, with more signs of congestion, a greater 
activation of the renin-angiotensin-aldosterone activation and worse renal function, yet the 
associations with outcomes were partly independent of these baseline parameters. Furthermore, 
patients with a higher FGF23 level were less well uptitrated with ACEi or ARBs during follow-up.  
FGF23 and volume overload 
FGF23 is a protein produced by osteocytes and osteoblasts, and has been identified as a 
phosphaturic hormone central to the regulation of phosphate homeostasis.[22] FGF23 is 
deregulated in a relatively early stage of CKD, contributing to abnormalities in bone and mineral 
metabolism.[23] Interestingly, a higher level of FGF23 has emerged as a strong risk factor for 
cardiovascular and all-cause mortality across the spectrum of CKD and after kidney 
transplantation.[24,25] These adverse effects of FGF23 are most likely beyond its direct effects on 
phosphate. This is suggested by the observation that hyperphosphatemia is associated with vascular 
calcification and ischemic cardiac events, whereas FGF23 is associated with HF and not with vascular 
calcifications.[4,26] Preclinical data demonstrated that FGF23 infusion leads to the development of 
left ventricular hypertrophy.[5] This may at least in part be corroborated with a role for FGF23 as a 
regulator of sodium homeostasis, through the sodium-chloride co-transporter in the distal tubule.[6] 
Also, recent data from a prospective observational study showed that FGF23 was independently 
associated with LV remodelling after myocardial infarction.[27] In the current study we demonstrate 
that  FGF23 levels were elevated in patients with worsening HF (median: 218 RU/mL) compared to 
previous levels reported in a community cohort (median: 70 RU/mL), and that higher FGF23 levels 
were associated with more signs of congestion.[19] Remarkably, all signs and symptoms of volume 
overload and congestion, i.e. oedema, orthopnoea, rales, elevated JVP and hepatomegaly were 
more common in patients with higher FGF23 levels. Also, in the multivariable model for FGF23, 
higher NT-proBNP, oedema, hepatomegaly, and lower haemoglobin and albumin, all signs of volume 
overload, were among the strongest predictors of FGF23 levels. Whether the association between 
FGF23 and volume overload is causal cannot be concluded from our observational data. It is 
noteworthy that in a recent study FGF23 did not markedly change in response to volume 
interventions that may suggest that FGF23 is a cause rather than a consequence of volume 
overload.[28] Plasma FGF23 levels were only measured at baseline in our study, and therefore we 
were not able to determine changes in plasma FGF23 in relation to the changes of signs of 
congestion and volume overload. Several studies showed an inverse relationship between renal 
function and FGF23 levels, consistent with our findings in worsening heart failure.[29,30] Of note, 
renal impairment was one of strongest predictors of FGF23 in our cohort.  
FGF23, circulating RAAS parameters and ACEi/ARB optimization 
In the current study, we found higher renin levels in patients with higher FGF23 levels; moreover, 
higher plasma aldosterone was a predictor of higher FGF23 levels in multivariable analysis, 
suggesting more pronounced RAAS activation in patients with higher FGF23. This can be related to 
the volume expansion that is also associated with higher FGF23. Alternatively, the association 
between higher plasma renin levels and FGF23 levels can be explained by the finding that FGF23 
increased the production of renin, by suppressing the generation of 1.25(OH)2 vitamin D, which is an 
established negative regulator of renin gene expression.[31] The association between FGF23 and 
RAAS-activity is of particular interest in the light of our finding that higher FGF23 levels were also 
associated with lower baseline prescription rates of ACEi or ARBs and less frequent use of guideline 
recommended target dose. Additionally, patients with higher FGF23 levels were also less likely to 
use an ACEi or ARB after 3 months of uptitration, and less frequently used target doses. In contrast, 
this association was not observed for beta-blocker therapy. This association between FGF23 and 
failure of ACEi/ARB uptitration remained significant after adjustment for baseline ACEi/ARB use, 
RAAS activation, renal function, and severity of heart failure, suggesting that FGF23 levels provide 
additional information regarding the tolerability of ACEi or ARBs. This observation may be mediated 
by impaired renal function in patients with high FGF23 levels, although the observed association 
persisted after adjustment for eGFR. Future studies should provide more insight in the relation 
between FGF23 and tolerability of RAAS blockade and effectiveness as this could be an  interesting 
and applicable feature of this biomarker.     
FGF23 and outcome 
Our findings that higher FGF23 levels are related with poorer clinical outcome in patients with 
worsening heart failure are in line with three small studies in stable chronic heart failure 
patients.[10-12] Recently, a larger study in patients with chronic heart failure found an increased risk 
of mortality in patients with a reduced ejection fraction, but not in patients with a preserved 
ejection fraction.[32] In our study, we showed for the first time a strong predictive value of higher 
FGF23 levels for adverse clinical outcomes, all-cause mortality and heart failure hospitalization in 
patients with worsening signs and symptoms of heart failure. In the highest quintile of FGF23 more 
than 50% of patients died during a median follow-up of 21 months. In contrast with previous 
findings in stable chronic heart failure, we did not observe a differential association with outcomes 
for patients with reduced versus preserved ejection fraction.[32] We recently published a risk score 
that was derived from BIOSTAT-CHF that included 42 demographic, clinical and biochemical 
variables.[21] FGF23 provided significant additive predictive value of adverse outcome on top of this 
risk score.  
Several mechanisms may explain the link between FGF23 and adverse outcome. FGF23 might 
increase fluid retention, and incomplete decongestion is associated with higher rehospitalisation 
rates and poorer outcome. Also, higher FGF23 might reflect patients with more severe renal 
dysfunction, a strong predictor of outcome in HF. The association with outcome was however partly 
independent of markers of volume status and renal function. This observation, along with data that 
FGF23 is also associated with mortality in patients with normal kidney function, suggests that FGF23 
is more than a marker of impaired renal function.[33] As FGF23 stimulates RAAS activity, this may 
cause left ventricular remodelling, volume overload, and subsequently adverse outcome. 
Additionally, higher levels of FGF23 may also indicate a more advanced disease status, as suggested 
by a longer disease duration, and the association with increased RAAS activation, which has shown 
to be an independent predictor of poor outcome in HF patients with chronic kidney disease.[34] 
Finally, FGF23 may prove to be a modifiable risk factor, as illustrated by a recent study in 
haemodialysis patients, showing that treatment with the calcimimetic cinacalcet lowered FGF23 
levels by about 50%, in association with lower risks of cardiovascular mortality and events.[35] 
Several studies, investigating the effect of phosphate binders and diet on FGF23 in CKD patients, are 
currently ongoing.  
 
Strengths and limitations 
To our knowledge this is the first study to investigate the role of FGF23 in patients with worsening 
symptoms of heart failure. Strengths of this study are the number of patients enrolled in this 
observational, European, multicentre, multinational cohort, and the extensive clinical data available, 
such as markers of RAAS activation. Limitations of this study include the observational design of this 
study, in which residual confounding potentially influenced our results. Also, both new-onset and 
worsening heart failure patients, as well as in- and outpatients were enrolled in our study. However, 
in subgroup analyses there was no difference in prognostic value. Data during hospitalization for 
heart failure and repeated measures of FGF23 and other biomarkers were not available, and we 
were therefore not able to establish the association between FGF23 and efficiency of decongestion. 
Furthermore, we were merely able to describe associations, and were unable to establish causality.  
 
Future directions 
Our study showed a strong association between higher FGF23 levels and adverse clinical outcome, 
however further studies are warranted to examined the underlying pathophysiology between higher 
FGF23 levels, hypervolemia, and RAAS activation in heart failure, and establish whether FGF23 is a 
cause or a consequence of fluid overload. Prospective studies targeting FGF23 levels in heart failure 
patients would shed more light on a potential causal role for FGF23 in fluid overload and adverse 
clinical outcomes in acute heart failure.  
 
Conclusion 
Higher FGF23 levels were associated with more severe heart failure, volume overload, worse renal 
function and an increased risk of all-cause mortality and heart failure hospitalization in patients with 
new-onset and worsening heart failure. In addition, higher plasma FGF23 levels are independently 
associated with less successful uptitration of guideline recommended ACEi/ARB therapy.  
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Figure legends 
Figure 1: Kaplan-Meier survival curve for the combined endpoint of all-cause mortality 
and heart failure (re)hospitalization according to quintiles of FGF23 
 
Table 1: baseline characteristics per quintile of FGF23 
Variable Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for 
trend 
N = 481 479 479 480 480  
FGF23 82.6 [68.2-93.7] 131.6 [117.3-
147.8] 
218.0 [190.2-
253.3] 
444.4 [364.7-579.0] 1862.0 [1118.0-
3351.0] 
 
Demographics       
Sex (% Male(n)) 80.5 (387) 74.5 (357) 76.2 (365) 65.8 (316) 70.6 (339) <0.001 
Age (years) 65.4±11.6 68.1±11.2 69.6±12 70.7±12.3 70.7±11.8 <0.001 
Race (% Caucasian(n)) 99.2 (477) 99.6 (477) 98.7 (473) 98.5 (473) 98.8 (474) 0.200 
BMI (kg/m2) 27.8±4.6 28.2±5.4 27.7±5.8 27.8±5.5 27.8±5.8 0.720 
Weight (kg) 82.3±16.1 83±17.9 81.4±19.6 80.7±18.4 81.3±19.4 0.118 
Height (kg) 171.9±8.8 171.4±9 171.2±9.3 169.8±9.3 170.5±8.9 0.001 
NYHA class (%(n))      <0.001 
I 5.0 (24) 3.5 (17) 1.7 (8) 0.8 (4) 0.0 (0)  
II 52.2 (251) 41.1 (197) 34.9 (167) 28.1 (135) 17.7 (85)  
III 35.8 (172) 44.9 (215) 48.6 (233) 51.5 (247) 61.3 (294)  
IV 5.4 (26) 7.3 (35) 12.1 (58) 16 (77) 18.3 (88)  
LVEF (%) 31.3±8.2 31±10.5 30.4±10.7 32.2±11.3 30±11.8 0.363 
HFPEF (%) 3.8 (17) 8.3 (36) 7.5 (32) 15.1 (65) 10.8 (45) <0.001 
Interventricular wall thickness (mm) 10.4±2.2 10.7±2.4 10.5±2.6 11.0±2.6 10.6±2.6 0.163 
Posterior wall thickness (mm) 10.2±2.0 10.2±2.2 10.4±2.2 10.5±2.7 10.3±2.2 0.269 
Clinical Profile       
Oedema (%(n)) 9.5 (35) 22.7 (90) 24 (95) 36.4 (148) 51.7 (222) <0.001 
Orthopnoea (%(n)) 20.6 (99) 25.9 (124) 35.7 (171) 40.6 (194) 50.9 (244) <0.001 
Rales > 1/3 up lung fields (%(n)) 12.5 (22) 20.9 (46) 21.1 (52) 17.8 (50) 22.2 (69) 0.078 
Jugular venous pressure (%(n)) 11.6 (36) 22.8 (74) 32.8 (104) 44.8 (138) 53.4 (171) <0.001 
Hepatomegaly (%(n)) 7.5 (36) 9.8 (47) 12.6 (60) 15.7 (75) 25.1 (120) <0.001 
Third heart tone (%(n)) 8.5 (41) 7.4 (35) 10 (48) 8.8 (42) 14.4 (69) 0.002 
Systolic Blood Pressure (mmHg) 128±20.9 128.6±22.4 123.8±21.2 124±22.6 119.2±20.2 <0.001 
Diastolic Blood Pressure (mmHg) 78±11.8 76.2±13 74.4±13.4 73.2±13.9 72.4±12.5 <0.001 
Heart Rate (beats/min) 75.7±17.1 79.2±20.1 79.6±19.3 80.8±19.3 83.3±19.9 <0.001 
Hospitalization       
Type of visit (%(n))      <0.001 
Scheduled outpatient clinic 45.1 (217) 35.3 (169) 25.3 (121) 18.8 (90) 14 (67)  
Unscheduled outpatient clinic 9.8 (47) 5.4 (26) 4.2 (20) 3.5 (17) 4.2 (20)  
Inpatient hospitalization 45.1 (217) 59.3 (284) 70.6 (338) 77.7 (373) 81.9 (393)  
Reason for visit (%(n))      <0.001 
Worsening heart failure 46.4 (223) 44.1 (211) 50.1 (240) 61.7 (296) 71.2 (342)  
New onset heart failure 28.3 (136) 34.4 (165) 30.3 (145) 24.8 (119) 19.6 (94)  
Other reason 25.4 (122) 21.5 (103) 19.6 (94) 13.5 (65) 9.2 (44)  
Diuretics iv (%(n)) 95.8 (137) 99 (206) 96.6 (254) 99.1 (325) 98.6 (360) 0.074 
Inotropes iv (%(n)) 8.5 (12) 7.2 (15) 11.5 (30) 8.3 (27) 17.2 (63) 0.001 
Nitrates iv (%(n)) 34 (48) 24.6 (51) 24.8 (65) 20.2 (66) 13.9 (51) <0.001 
Heart Failure History       
Years since first diagnosis 0.4 [0.2-1.5] 3 [0.5-5.9] 0.6 [0.1-5] 3.1 [0.3-7.7] 3.9 [1-7.5] 0.287 
NYHA class prior to decompensation/worsening HF (%(n))    <0.001 
I 13.1 (63) 11.1 (53) 10.4 (50) 6.2 (30) 4.4 (21)  
II 52.2 (251) 46.6 (223) 43.4 (208) 44 (211) 43.8 (210)  
III 21 (101) 26.3 (126) 30.7 (147) 31.2 (150) 37.7 (181)  
IV 2.7 (13) 3.3 (16) 3.8 (18) 2.9 (14) 4.2 (20)  
Previous HF hospitalization (%(n)) 24.1 (116) 26.5 (127) 34.2 (164) 35.4 (170) 39.2 (188) <0.001 
Medical History       
Hypertension (%(n)) 62.8 (302) 63 (302) 63.7 (305) 63.7 (306) 58.5 (281) 0.266 
Atrial fibrillation (%(n)) 26 (125) 42.8 (205) 46.3 (222) 51.7 (248) 59.8 (287) <0.001 
Coronary artery disease (%(n)) 41.6 (200) 40.9 (196) 44.3 (212) 49.6 (238) 49.6 (238) 0.001 
Myocardial infarction (%(n)) 37 (178) 34.7 (166) 38.4 (184) 40 (192) 42.1 (202) 0.027 
PCI (%(n)) 22.2 (107) 19.6 (94) 21.9 (105) 24.4 (117) 21.5 (103) 0.596 
CABG (%(n)) 13.1 (63) 14.6 (70) 15.4 (74) 20.8 (100) 22.1 (106) <0.001 
Pacemaker (%(n)) 4.2 (20) 5.8 (28) 8.6 (41) 8.8 (42) 9 (43) 0.001 
ICD (%(n)) 7.7 (37) 5.6 (27) 5.6 (27) 9.2 (44) 12.9 (62) <0.001 
Diabetes mellitus (%(n)) 27.2 (131) 30.7 (147) 29.6 (142) 36.7 (176) 37.9 (182) <0.001 
Peripheral artery disease (%(n)) 6.9 (33) 9.2 (44) 10.9 (52) 14.6 (70) 14 (67) <0.001 
Medication       
ACE-inhibitors or Angiotensin receptor 
blockers (%(n)) 
78.8 (379) 76 (364) 76.4 (366) 67.1 (322) 62.1 (298) <0.001 
   Target dose (%(n)) 16.2 (78) 16.1 (77) 13.2 (63) 11.7 (56) 7.7 (37) <0.001 
Beta-blockers (%(n)) 85.9 (413) 86.2 (413) 84.3 (404) 80.4 (386) 78.8 (378) <0.001 
   Target dose (%(n)) 4 (19) 4.6 (22) 5.4 (26) 7.3 (35) 5.8 (28) 0.048 
Loop diuretics (%(n)) 99.2 (477) 99.4 (476) 99.4 (476) 100 (480) 99.8 (479) 0.055 
Aldosterone antagonists (%(n)) 54.5 (262) 53.9 (258) 53.7 (257) 51.5 (247) 55.2 (265) 0.897 
Laboratory values       
Haemoglobin (g/dL) 13.9 [12.9-14.8] 13.8 [12.6-14.8] 13.3 [12.1-14.6] 12.8 [11.5-14.1] 12.3 [10.9-13.7] <0.001 
Creatinine (umol/L) 87.5 [74-104] 94.4 [77.7-117.6] 100 [87-128] 113.6 [89.8-150.3] 122 [97-159.1] 0.377 
Urea (mmol/L) 8.2 [6-12.9] 9.5 [6.8-15] 11.1 [7.7-17.1] 12 [8.2-19.4] 15.7 [9.6-25.3] <0.001 
eGFR (ml/min/1.73m2) 75.9 [61.6-89.4] 64.8 [50.5-83.3] 60 [45.3-75.9] 51.2 [37.3-68.8] 47.6 [33.2-65] <0.001 
Sodium (mmol/L) 140 [138-142] 140 [138-142] 140 [138-142] 140 [137-142] 138 [136-141] <0.001 
Potassium (mmol/L) 4.3 [4-4.6] 4.3 [4-4.6] 4.2 [3.9-4.6] 4.2 [3.9-4.5] 4.2 [3.8-4.6] 0.010 
BNP (ng/mL) 223.8 [81.5-503.9] 645.9 [354.5-
1037.9] 
637 [507.5-975] 822.5 [450.5-
1517.2] 
1305 [872.2-2522.5] <0.001 
NT-proBNP (ng/L) 2365.5 [1065.8-
4541.8] 
3057 [1829.5-
5221] 
3960 [2292.5-
7509.2] 
5365.5 [2810.8-
9914.2] 
7054.5 [3397.5-
11861] 
<0.001 
Calcium (mmol/L) 1.8 [1.6-2.1] 1.8 [1.6-2.1] 1.8 [1.5-2] 1.7 [1.5-2] 1.7 [1.4-1.9] <0.001 
Phosphate (mmol/L) 0.8 [0.7-1] 0.9 [0.7-1.1] 0.9 [0.7-1] 0.9 [0.7-1] 0.9 [0.6-1.1] 0.353 
Albumin (g/L) 35 [31-40] 34 [29-40] 33 [28-38] 31 [26-36] 30 [24-34] <0.001 
Aldosterone (pg/mL) 94.9 [44-194.5] 93 [45-167] 92 [41.4-190] 88 [43-185] 106.5 [43-257] <0.001 
Renin (UI/mL) 62.8 [23.4-186.1] 81.2 [24-205.7] 90 [29.2-259.4] 95.4 [34-255.2] 134.8 [37.4-436.1] <0.001 
 
Abbreviations: BMI: Body Mass Index; BNP: Blood Natriuretic Peptide; CABG: Coronary Artery Bypass Graft; FGF23: Fibroblast Growth Factor 23; eGFR: estimated 
Glomerular Filtration Rate; HF: Heart Failure; HFpEF: Heart Failure with a Preserved Ejection Fraction; ICD: Implantable Cardiac Defibrillator; LVEF: Left Ventricular Ejection 
Fraction; NT-proBNP: N-terminal pro Blood Natriuretic Peptide; NYHA: New York Heart Association; PCI: Percutaneous Coronary Intervention.  
Table 2: FGF23 and ACEi/ARB use after 3 months of uptitration 
 ACEi/ARB use  Target dose  
Log FGF23  OR (CI)  P-value  OR (CI)  P-value  
Univariable  0.62 (0.57-0.68)  <0.001  0.69 (0.62-0.76)  <0.001  
Multivariable*  0.79 (0.70-0.90)  <0.001  0.76 (0.65-0.87)  <0.001  
*Corrected for age, sex, eGFR, aldosterone, renin, calcium, albumin, phosphate, NYHA class, and ACEi/ARB use 
at baseline  
Abbreviations: ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CI: confidence 
interval; FGF23: Fibroblast Growth Factor 23; OR: odds ratio 
 
Table 3: Cox regression analysis for FGF23, and all-cause mortality, heart failure rehospitalisation, and the combined 
endpoint 
 All-cause mortality or HF hospitalization All-cause mortality 
  Univariable Multivariable*  Univariable Multivariable* 
 Number of 
events (%(n)) 
HR (95% CI) P-value HR (95% CI) P-value Number of 
events (%(n)) 
HR (95% CI) P-value HR (95% CI) P-value 
Log FGF23 981 (41%) 1.49 (1.43-1.56) <0.001 1.15 (1.08-1.22) <0.001 631 (26) 1.57 (1.49-1.66) <0.001 1.17 (1.09-1.26) <0.001 
           
Quintile 1 19.3 (93) 1.0 (Reference) Ref 1.0 (Reference) Ref 9.4 (45) 1.0 (Reference) Ref 1.0 (Reference) Ref 
Quintile 2 29.4 (141) 1.58 (1.22-2.06) <0.001 1.31 (0.99-1.74) 0.059 17.5 (84) 1.93 (1.34-2.78) <0.001 1.57 (1.06-2.34) 0.025 
Quintile 3 39.2 (188) 2.28 (1.78-2.93) <0.001 1.36 (1.03-1.79) 0.031 19.6 (94) 2.16 (1.51-3.11) <0.001 1.25 (0.84-1.87) 0.268 
Quintile 4 49.6 (238) 3.31 (2.60-4.21) <0.001 1.56 (1.19-2.06) 0.002 36 (173) 4.56 (3.27-6.35) <0.001 1.94 (1.33-2.84) <0.001 
Quintile 5 66.9 (321) 5.35 (4.24-6.75) <0.001 1.95 (1.47-2.58) <0.001 49 (235) 6.89 (4.99-9.51) <0.001 2.10 (1.43-3.08) <0.001 
*Corrected for the BIOSTAT risk model with addition of calcium, albumin, renin, aldosterone, phosphate, and estimated Glomerular Filtration Rate. 
Abbreviations: FGF23: Fibroblast Growth Factor 23; HF: heart failure; HR: hazard ratio; ref: reference
  
 
 
 
